A priority review voucher isn’t tied to one drug

Three programs, the same voucher mechanics

FDA runs three parallel priority review voucher programs with nearly identical mechanics but separate statutory homes. The rare pediatric disease voucher, at 21 U.S.C. 360ff, rewards approval of a drug or biologic for a rare pediatric disease that meets the statute's own criteria. The tropical disease voucher, created under section 524 of the Act and codified at 21 U.S.C. 360n-1, rewards approval of a product for a named tropical disease. A third program, added by the 21st Century Cures Act in 2016 and codified at 21 U.S.C. 360bbb-4a, rewards approval of a medical countermeasure against an agent FDA has identified as a material threat. All three hand the sponsor a voucher entitling its holder to priority review — a shorter FDA review clock — for a single future human drug application that has nothing to do with the disease or threat that earned it.

The voucher is an asset, not a credential

Nothing in any of the three statutes ties the voucher to the sponsor that earned it. FDA's own approval letters confirm the voucher can be transferred, including by sale, with no limit on how many times it changes hands before someone redeems it, and sale prices for rare pediatric vouchers have run from tens of millions of dollars to several hundred million in reported transactions. Each new holder has to notify FDA of the change in ownership within 30 days, but that notice is a bookkeeping step, not an application for FDA's approval of the transfer — the statute doesn't give FDA a vote over who's allowed to hold a voucher, only a record of who currently does.

Redeeming it is a binding promise, not a formality

Using the voucher is where the statute tightens up. The holder has to notify FDA of its intent to submit a voucher-redeemed application at least 90 days before the planned submission date, and that notice is itself a binding commitment to pay the associated user fee once the application is filed — a fee FDA sets for the fiscal year the application arrives in, running near $1.8 million for fiscal year 2027. A holder can still sell the voucher after giving that 90-day notice, as long as the application hasn't been submitted yet, but the fee obligation the notice created doesn't disappear with the sale; it follows whoever actually files.

The award authority can lapse even though an issued voucher doesn't

The rare pediatric disease program's authority to award new vouchers is not permanent, and Congress has let it lapse before: the program's authorization expired at the end of 2024, and FDA's authority to issue new rare pediatric vouchers stayed lapsed until the Consolidated Appropriations Act, 2026 revived it and extended that authority through September 30, 2029. A voucher already issued and sitting in a sponsor's portfolio keeps its value through a gap like that; it's the ability to earn a new one that the lapse actually freezes. The tropical disease program carries no equivalent sunset at all — it was the first of the three enacted and the only one Congress wrote without an expiration date — so a reauthorization fight over the pediatric program says nothing about whether the other two are still open for new awards. A tracker that records only “voucher program: active” has nowhere to show which program, and which side of the earn-versus-hold distinction, a given asset sits on.

Where this meets the file

A voucher tracking template that keeps the earning statute, the current transfer chain, and the 90-day notice date as separate required fields — not folded into a single “priority review voucher” checkbox — is previewed in the launch catalog alongside this week's other drug-lifecycle templates. If your program tracks a voucher's chain of custody differently, the shelf takes that correction directly.